Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas

被引:0
|
作者
Long, Jiang [1 ,2 ]
Lang, Zhen-Wei [3 ]
Wang, Hua-Guang [4 ]
Wang, Tai-Ling [5 ]
Wang, Bao-En [1 ]
Liu, Si-Qi [6 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing 100050, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Dept Hepatol, Beijing 100069, Peoples R China
[3] Capital Med Univ, Beijing Youan Hosp, Dept Pathol, Beijing 100069, Peoples R China
[4] Capital Med Univ, Beijing Chaoyang Hosp, Dept Pharmaceut Affairs, Beijing 100020, Peoples R China
[5] China Japan Friendship Hosp, Dept Pathol, Beijing 100029, Peoples R China
[6] Chinese Acad Sci, Beijing Genom Inst, Beijing 101300, Peoples R China
关键词
glutamine synthetase; phenazine biosynthesis-like domain-containing protein; proteomics; ALPHA-FETOPROTEIN; LIVER; METABOLISM; EXPRESSION; PROLIFERATION; BIOMARKER; ZONATION; GROWTH; HSP70;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Hepatocellular carcinoma (HCC) is a highly malignant tumor with a poor prognosis. Because small HCCs possess most of the characteristics of early HCC, we investigated small HCCs to screen potential biomarkers for early diagnosis. METHODS Proteins were extracted from 10 sets of paired tissue samples from HBV-infected small-HCC patients. The extracted proteins were well resolved by two-dimensional electrophoresis. These HCC-associated proteins were then identified by MALDI-TOF/TOF MS following image analysis. Western blotting and immunohistochemistry were used to assess glutamine synthetase (GS) and phenazine biosynthesis-like domain-containing protein (PBLD) expression in liver tissue. Enzyme-linked immunosorbent assays in 152 serum samples (from 49 healthy donors, 24 patients with liver cirrhosis, and 79 with HCC) were used to further assess the significance of GS clinically. RESULTS: Fifteen up-regulated and three down-regulated proteins were identified. Western blotting confirmed GS overexpression and decreased PBLD expression in liver tissue. Immunohistochemistry showed that GS was expressed in 70.0% (84/120) of HCCs and 35.8% (43/120) of nontumor tissues; PBLD was expressed in 74.2% (89/120) of nontumor tissues and 40.8% (49/120) of HCCs. The Chi-square test showed significant expression differences between HCCs and adjacent tissues. Consistent with this, serum GS levels in HCC patients were significantly higher than those in liver cirrhosis patients and healthy donors, while the latter two groups were also significantly different. In addition, a diagnostic cutoff value of 2.6 mg/ml was used for GS; it was elevated in 19 (76.0%) of 25 HCC patients with AFP <= 20 ng/ml and 47 (88.7%) of 53 HCC patients with AFP <= 200 ng/ml. CONCLUSION: GS and PBLD are abnormally expressed in most HCCs. GS may be a novel serum marker for early HCC, especially for those patients with low AFP levels (<= 200 ng/ml). (Hepatobiliary Pancreat Dis Int 2010; 9: 296-305)
引用
收藏
页码:296 / 305
页数:10
相关论文
共 50 条
  • [1] Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected smal hepatocel ular carcinomas
    Jiang Long
    Department of Hepatology
    Department of Pharmaceutical Affairs
    Department of Pathology
    Beijing Genomics Institute
    [J]. Hepatobiliary & Pancreatic Diseases International, 2010, 9 (03) : 296 - 305
  • [2] Glutamine synthetase and hepatocellular carcinoma
    Jiang, Jinghua
    Hu, Yiting
    Fang, Dazhang
    Luo, JianSheng
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (10)
  • [3] Glutamine synthetase: a tumor suppressor in hepatocellular carcinoma?
    Dai, Weiwei
    Zong, Wei-Xing
    [J]. JOURNAL OF MOLECULAR CELL BIOLOGY, 2023, 15 (01)
  • [4] ANGIOGRAPHY OF SMALL HEPATOCELLULAR CARCINOMAS - ANALYSIS OF 105 RESECTED TUMORS
    TAKAYASU, K
    SHIMA, Y
    MURAMATSU, Y
    GOTO, H
    MORIYAMA, N
    YAMADA, T
    MAKUUCHI, M
    YAMASAKI, S
    HASEGAWA, H
    OKAZAKI, N
    HIROHASI, S
    KISHI, K
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1986, 147 (03) : 525 - 529
  • [5] Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma
    Zhang, Bo
    Liu, Kai
    Zhang, Jian
    Dong, Liwei
    Jin, Zhichao
    Zhang, Xinji
    Xue, Feng
    He, Jia
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (11): : 20722 - +
  • [6] Differential proteomic analysis of hepatocellular carcinoma
    Corona, Giuseppe
    De Lorenzo, Elisa
    Elia, Caterina
    Simula, Maria Paola
    Avellini, Claudio
    Baccarani, Umberto
    Lupo, Francesco
    Tiribelli, Claudio
    Colombatti, Alfonso
    Toffoli, Giuseppe
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 36 (01) : 93 - 99
  • [7] Differential Proteomic Analysis of Hepatocellular Carcinoma
    Baccarani, Umberto
    Corona, Giuseppe
    De Lorenzo, Elisa
    Elia, Caterina
    Simula, Maria Paola
    Avellini, Claudio
    Lupo, Francesco
    Lorenzin, Dario
    Adani, Luigi
    Rossetto, Anna
    Tiribelli, Claudio
    Colombatti, Alfonso
    Toffoli, Giuseppe
    [J]. LIVER TRANSPLANTATION, 2010, 16 (06) : S220 - S220
  • [8] Patterns of glutamine synthetase expression as marker of beta catenin activation in hepatocellular adenomas
    Balabaud, C.
    Sempoux, C.
    Gouw, A. S.
    Cappellen, D.
    Bisig, B.
    Bail, B. L.
    Bioulac-Sage, P.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S420 - S421
  • [9] Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma
    Osada, T
    Nagashima, I
    Tsuno, NH
    Kitayama, J
    Nagawa, H
    [J]. JOURNAL OF HEPATOLOGY, 2000, 33 (02) : 247 - 253
  • [10] Predictive factor for early recurrence of resected hepatocellular carcinoma
    Kato, T.
    Noda, H.
    Yoshizawa, A.
    Kasahara, N.
    Watanabe, F.
    Endo, Y.
    Kaneda, Y.
    Rikiyama, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29